Polymun was founded in 1992 by Prof. Hermann Katinger. It is a private company fully owned by the Katinger family. Revenues are generated by contract development and manufacturing as well as creating liposomal formats of drugs for contract partners. These revenues are invested in the proprietary product pipeline and the further development of technology platforms. The R&D projects and technologies are open for co-development and licensing. Polymun operates in accordance with current GMP guidelines and holds an Austrian production license for pharmaceuticals (§63 Austrian Pharmaceutical Law) thus meeting the EU requirements for drug manufacturing. The last inspection by the Austrian regulatory authority AGES on behalf of EMA has taken place in April 2017, the last inspection by FDA in October 2013.
COMPETENCE & SERVICES
The two core competences of Polymun are the development and manufacture of biopharmaceuticals using mammalian cell technology as well as Polymun's innovative liposome technology and expertise. Today, Polymun can apply this drug delivery platform to all kinds of pharmaceutically active ingredients. The industrial applicability in scale and price is a common focus throughout all projects and technologies.